The Research Technologies program is pleased to co-sponsor biomedical symposia and other educational events that align with the goals and objectives of ACTSI. The aim in sponsoring these types of events is to:
  • Foster and increase interdisciplinary collaboration opportunities;
  • Promote novel methodological development;
  • Support education and training in technology development; and
  • Facilitate the process of commercializing promising technologies.
In the past, Research Technologies supported events that have sparked important new collaborations, led to funding for new initiatives, and/or provided the opportunity for young translational investigators to interface with scientific networks in their area of research.


Those eligible to apply for these funds include any faculty or staff affiliated with the following three institutions: Emory University, Georgia Institute of Technology, and Morehouse School of Medicine (MSM).

Previously Supported Events

Application Process

To apply for support (up to $5,000) please click here to complete the required application. Applications must be received no later than 30 days prior to the start of the event. For the application to be considered you must include:
  1. A detailed budget for the entire event, which includes a breakdown of how Research Technologies funds will be spent; and
  2. A detailed description of how the event aligns with the goals and objectives of the ACTSI and Research Technologies.

PLEASE NOTE: Research Technologies will no longer fund general costs (i.e. parking, printing materials, etc.). The funds must be used to support a specific component of the event that is integral to the success of the event and that will have a lasting impact on the attendees. Our funding is limited and moving forward we are only able to sponsor events where our support will have a clearly identified impact on the technology development and translational research community. Also, please note that funds can only be used to cover expenses allowable under the federal cost accounting standards.

Apply Now

Review Criteria

Priority will be given to applications with a high level of promise for demonstrating strong potential to build capacity for technology development and translational research across the Atlanta region.

Promotion and Marketing

If Research Technologies funds are awarded to sponsor the event, the ACTSI logo should appear in the sponsorship section for all event-related materials, including promotional materials (flyers, websites, mailers, etc.) and programs. Every effort should be made to market this event to all ACTSI partner institutions (Emory, Georgia Tech, and MSM). Before going to print or web, materials which contain the logo must be reviewed and approved by the ACTSI Director of Communications. Please send a copy of all announcements and promotional materials, as well as links to event information, to the ACTSI Director of Communications, Elizabeth Thompson (epthomp@emory.edu).

Reporting Requirements

A brief progress report is requested within 30 days following the event. The report should include a list of attendees, particular highlights from the event, emergent themes, plans for follow-on events or meetings, and other significant outcomes.

Also, in an effort to evaluate how our support funds are making an impact. Latrice Rollins (lrollins@msm.edu) from the ACTSI Tracking & Evaluation program will be in contact regarding participation in the post event survey.


Upcoming Events

View All Events

Funding News


Healthcare Innovation Symposium XX: Health Services Research-October 26

Presented by Lisa Simpson, MB, BCh, MPH, FAAP, President and CEO, AcademyHealth and hosted by the Emory-Georgia Tech Healthcare Innovation Program and Georgia CTSA from noon-2:00 p.m. in Emory School of Medicine.


CTSA-supported Models Contribute to the First Possible Drug Treatment for Lymphedema

A recent study led by scientists at the Stanford University School of Medicine uncovered for the first time the molecular mechanism responsible for triggering lymphedema, as well as a drug with the potential for inhibiting that process....